Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 128 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016', provides in depth analysis on Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted pipeline therapeutics. 

The report provides comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.)
- The report reviews Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) Overview 10
Therapeutics Development 11
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Stage of Development 11
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Therapy Area 12
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Indication 13
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Companies 18
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Universities/Institutes 22
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Therapeutics Assessment 24
Assessment by Monotherapy/Combination Products 24
Assessment by Mechanism of Action 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Companies Involved in Therapeutics Development 30
Abeome Corporation 30
AFFiRiS AG 31
Alnylam Pharmaceuticals, Inc. 32
Amgen Inc. 33
Betagenon AB 34
BioLingus AG 35
Catabasis Pharmaceuticals, Inc. 36
Daiichi Sankyo Company, Limited 37
Eli Lilly and Company 38
HitGen LTD 39
Kowa Company, Ltd. 40
Kymab Limited 41
MedImmune, LLC 42
Merck & Co., Inc. 43
Pfizer Inc. 44
Planet Biotechnology Inc. 45
Regeneron Pharmaceuticals, Inc. 46
Serometrix, LLC 47
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 48
Thetis Pharmaceuticals LLC 49
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Drug Profiles 50
(atorvastatin calcium + TP-452) - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
alirocumab - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ALN-PCSsc - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
ATH-04 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
ATH-06 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Biologics to Target PCSK-9 for Hypercholesterolemia - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
bococizumab - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
CAT-2000 Series - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
DS-9001 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
evolocumab - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
K-312 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
KY-1020 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
LY-3015014 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
MEDI-4166 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
O-304 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Recombinant Protein to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Small Molecules to Inhibit PCSK9 for Coronary Artery Disease and Metabolic Disorders - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
SX-PCK9 - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
TP-452 - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Dormant Projects 106
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Discontinued Products 108
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Featured News & Press Releases 109
Jun 02, 2016: The Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si 109
May 24, 2016: New Cholesterol Treatment Now Available for Canadians 109
May 24, 2016: New study results show cholesterol-lowering medication, Repatha (evolocumab), lowers LDL-C when self-administered in at-home setting 111
May 23, 2016: The Results From A One Year Treatment Of Repatha Presented At The Annual Meeting Of The Japan Diabetes Society 112
May 16, 2016: ICON and Pfizer Honoured as Clinical Research Team of the Year at the Clinical and Research Excellence Awards 113
May 11, 2016: Cigna's New Value-Based Contract with Sanofi/Regeneron for Praluent 114
May 11, 2016: Cigna's New Value-Based Contract with Amgen for Repatha 115
May 06, 2016: Innovative cholesterol-lowering treatment, Praluent (alirocumab), approved by NICE for people with raised cholesterol levels who are at significantly high risk of a heart attack or stroke 116
May 06, 2016: NICE Sets Out Draft Recommendations For Repatha (Evolocumab) In Final Appraisal Determination 118
Apr 26, 2016: Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled 119
Apr 21, 2016: Amgen Astellas Biopharma And Astellas Introduce Repatha (Evolocumab) For The Treatment Of High Cholesterol 120
Apr 04, 2016: New study results of Repatha (evolocumab) in statin-intolerant patients published in Journal of the American Medical Association 121
Apr 03, 2016: Positive Efficacy And Tolerability Study Of Repatha (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association" 123
Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab 124
Mar 23, 2016: Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy 125
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 127
Disclaimer 128

List of Tables

Number of Products under Development for, H1 2016 11
Number of Products under Development by Therapy Area, H1 2016 12
Number of Products under Development by Indication, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Comparative Analysis by Unknown Stage Development, H1 2016 17
Number of Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Development by Companies, H1 2016 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H1 2016 22
Products under Investigation by Universities/Institutes, H1 2016 23
Assessment by Monotherapy/Combination Products, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Pipeline by Abeome Corporation, H1 2016 30
Pipeline by AFFiRiS AG, H1 2016 31
Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 32
Pipeline by Amgen Inc., H1 2016 33
Pipeline by Betagenon AB, H1 2016 34
Pipeline by BioLingus AG, H1 2016 35
Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016 36
Pipeline by Daiichi Sankyo Company, Limited, H1 2016 37
Pipeline by Eli Lilly and Company, H1 2016 38
Pipeline by HitGen LTD, H1 2016 39
Pipeline by Kowa Company, Ltd., H1 2016 40
Pipeline by Kymab Limited, H1 2016 41
Pipeline by MedImmune, LLC, H1 2016 42
Pipeline by Merck & Co., Inc., H1 2016 43
Pipeline by Pfizer Inc., H1 2016 44
Pipeline by Planet Biotechnology Inc., H1 2016 45
Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 46
Pipeline by Serometrix, LLC, H1 2016 47
Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016 48
Pipeline by Thetis Pharmaceuticals LLC, H1 2016 49
Dormant Projects, H1 2016 106
Dormant Projects (Contd..1), H1 2016 107
Discontinued Products, H1 2016 108